Pharmaceutical News

RSS

Humana Pharmacy agrees to highest standards of transparency for prescription-drug pricing

Humana Inc. announced today that its Humana Pharmacy Solutions division is one of only five pharmacy-benefit managers (PBMs) in the U.S. to agree to the highest level of transparency for prescription-drug pricing set by the HR Policy Association.

7 Oct 2010

Sucampo submits marketing application for Amitiza drug

Sucampo Pharmaceuticals, Inc. and Abbott today announced that Sucampo Pharma Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc., has submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market Amitiza (lubiprostone) 24 mcg for the treatment of chronic idiopathic constipation (CIC).

7 Oct 2010

Semi-synthetic opioid may improve withdrawal symptoms in infants

Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.

7 Oct 2010

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

The company Synthetic Genomics Inc. (SGI) and the not-for-profit research organization, the J. Craig Venter Institute (JCVI) today announced the formation of a new company, Synthetic Genomics Vaccines Inc. (SGVI).

7 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

ANDA approved for Losartan Potassium Tablets USP, Losartan Potassium and Hydrochlorothiazide Tablets

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application for Losartan Potassium Tablets USP, 25mg, 50mg and 100mg as well as Losartan Potassium and Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. Food and Drug Administration. Both products are available for immediate shipment to wholesalers and pharmacies nationwide.

7 Oct 2010

Quintiles, SNUH announce clinical research partnership

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today celebrated its 10th year anniversary in South Korea by announcing a strategic alliance with the Seoul National University Hospital (SNUH) as part of its unique Prime Site program. SNUH is Quintiles' second Prime Site in Asia, adding to six other existing sites located in the United States, Europe and Africa.

7 Oct 2010

Roche receives development and commercialization rights for danoprevir drug

InterMune, Inc. today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.

7 Oct 2010

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

BioTrends Research Group, Inc. recently published its TreatmentTrends: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology. The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease patients.

7 Oct 2010

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades.

7 Oct 2010

Gymnemic acid nanocrystals could help develop soluble drug compounds

Researchers in India have demonstrated that producing nanoscopic crystals of a pharmaceutical product can allow the medication to be absorbed by the gut even if the drug is not soluble in water.

7 Oct 2010

Raloxifene drug may be useful in treating kidney disease in women: Study

The osteoporosis drug raloxifene may be useful in treating kidney disease in women, suggests a new study led by Michal Melamed, M.D., M.H.S., assistant professor of medicine and epidemiology & population health at the Albert Einstein College of Medicine of Yeshiva University.

7 Oct 2010

FDA awards cooperative agreement to PAHO to develop information hub for medical products

The U.S. Food and Drug Administration today announced the award of a $904,000 cooperative agreement to the Pan American Health Organization (PAHO) to research and develop an information hub for medical products and related regulatory processes and systems in the Americas Region.

7 Oct 2010

BioNJ creates special diagnostics committee to focus on personalized medicine

The strength of New Jersey's life sciences community and its unique ability to contribute to one of medicine's fastest growing areas—personalized medicine—has prompted BioNJ, the voice of the biotechnology industry in New Jersey, to create a special Diagnostics Committee.

7 Oct 2010

FDA unveils report to advance regulatory science

The U.S. Food and Drug Administration today unveiled a report outlining the agency's plans to advance regulatory science through its Regulatory Science Initiatie.

7 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

CoreLab Partners completes first ever regulatory mandated Thorough QT study in the Asia Pacific Rim

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).

6 Oct 2010

Pharmaceutical News

Humana Pharmacy agrees to highest standards of transparency for prescription-drug pricing

Sucampo submits marketing application for Amitiza drug

Semi-synthetic opioid may improve withdrawal symptoms in infants

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

ANDA approved for Losartan Potassium Tablets USP, Losartan Potassium and Hydrochlorothiazide Tablets

Quintiles, SNUH announce clinical research partnership

Roche receives development and commercialization rights for danoprevir drug

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Gymnemic acid nanocrystals could help develop soluble drug compounds

Raloxifene drug may be useful in treating kidney disease in women: Study

FDA awards cooperative agreement to PAHO to develop information hub for medical products

BioNJ creates special diagnostics committee to focus on personalized medicine

FDA unveils report to advance regulatory science

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

CoreLab Partners completes first ever regulatory mandated Thorough QT study in the Asia Pacific Rim

Ibuprofen provides pain relief within two hours in 49% of migraine sufferers

Research to focus on effective use of artemisinin stocks for malaria

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News